Alpha 2.0
Login Register
» Articles » PMID: 32587062

Disease Duration, Age at Diagnosis and Organ Damage Are Important Factors for Cardiovascular Disease in SLE

Overview
Journal Lupus Sci Med
Specialties Allergy & Immunology
Rheumatology
Date 2020 Jun 27
PMID 32587062
Citations 10
Authors
Ola Nived
Ragnar Freyr Ingvarsson
Anna Joud
Petrus Linge
Helena Tyden
Andreas Jonsen
Anders A Bengtsson
Affiliations
Soon will be listed here.
Abstract

Objective: To report the incidence rate ratios (IRR) of acute myocardial infarctions (AMI) and cerebrovascular events (CVE) in incident SLE cases from a defined population. To study the risk factors for cardiovascular events in all patients with SLE at our unit.

Methods: Patients with SLE diagnosed from 1981 to 2006 were followed through to 2016. IRRs of AMI and CVE were calculated. The AMI and CVE incidence patterns for patients with SLE were studied in relation to hypertension, smoking, renal dysfunction, anticardiolipin (aCL) antibodies at diagnosis, disease duration and organ damage before an event.

Results: 262 patients with SLE were included in the study; of these 175 were from the defined population. Overall, 37 AMI and 44 CVE were recorded. An increased IRR of 3 for AMI was found (p<0.001). Smoking, hypertension and reduced renal function were risk factors for AMI. An increased IRR of 3.3 for ischaemic CVE was found for women (p<0.001). Hypertension and aCL were risk factors for CVE. Organ damage before events was increased.

Conclusions: Cardiovascular events are increased in SLE and are associated with hypertension, smoking and increased damage rate.

Citing Articles

Coronary artery calcification progression and renal involvement in patients with systemic lupus erythematosus: a longitudinal cohort study.

Zinglersen L, Zinglersen A, Myhr K, Hermansen M, Kofoed K, Fuchs A Rheumatol Int. 2025; 45(1):26.

PMID: 39804493 PMC: 11729070. DOI: 10.1007/s00296-025-05785-8.

Increased cardiovascular risk in Korean patients with systemic lupus erythematosus: a population-based cohort study.

Han J, Cho S, Kim H, Jeon Y, Kang G, Jung S Sci Rep. 2024; 14(1):1082.

PMID: 38212487 PMC: 10784514. DOI: 10.1038/s41598-024-51546-1.

Cardiac Abnormalities in Relation to the Disease Activity Index Among Systemic Lupus Erythematosus Patients in a Tertiary Hospital: A Cross-Sectional Study.

Attuquayefio S, Doku A, Dey D, Agyekum F, Akumiah F, Kweki A Cureus. 2023; 15(11):e49495.

PMID: 38152811 PMC: 10751590. DOI: 10.7759/cureus.49495.

Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease.

Blachut D, Przywara-Chowaniec B, Tomasik A, Kukulski T, Morawiec B Biomedicines. 2023; 11(10).

PMID: 37893187 PMC: 10604001. DOI: 10.3390/biomedicines11102814.

Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis.

Andraos R, Ahmad A, Eriksson P, Dahlstrom O, Wirestam L, Dahle C Lupus Sci Med. 2022; 9(1).

PMID: 36581379 PMC: 9806068. DOI: 10.1136/lupus-2022-000732.

References
1.
Jonsson H, Nived O, Sturfelt G, Silman A . Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol. 1990; 29(3):185-8. DOI: 10.1093/rheumatology/29.3.185. View
2.
Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y . Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation.... Thromb Haemost. 2004; 91(5):967-76. DOI: 10.1160/TH03-10-0608. View
3.
Tarr T, Papp G, Nagy N, Cserep E, Zeher M . Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol. 2016; 36(2):327-333. DOI: 10.1007/s10067-016-3492-6. View
4.
Bartels C, Buhr K, Goldberg J, Bell C, Visekruna M, Nekkanti S . Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014; 41(4):680-7. PMC: 3975689. DOI: 10.3899/jrheum.130874. View
5.
Bengtsson C, Ohman M, Nived O, Rantapaa Dahlqvist S . Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus. 2011; 21(4):452-9. DOI: 10.1177/0961203311425524. View